Terms: = Lymphoma AND CREBBP, CBP, 1387, ENSG00000005339, RSTS, RTS AND Clinical Outcome
8 results:
1. Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell lymphoma.
Zhu Y; Fu D; Shi Q; Shi Z; Dong L; Yi H; Liu Z; Feng Y; Liu Q; Fang H; Cheng S; Wang L; Tian Q; Xu P; Zhao W
Front Immunol; 2022; 13():842439. PubMed ID: 35401516
[TBL] [Abstract] [Full Text] [Related]
2. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.
Pedrosa L; Fernández-Miranda I; Pérez-Callejo D; Quero C; Rodríguez M; Martín-Acosta P; Gómez S; González-Rincón J; Santos A; Tarin C; García JF; García-Arroyo FR; Rueda A; Camacho FI; García-Cosío M; Heredero A; Llanos M; Mollejo M; Piris-Villaespesa M; Gómez-Codina J; Yanguas-Casás N; Sánchez A; Piris MA; Provencio M; Sánchez-Beato M
Sci Rep; 2021 Jan; 11(1):1886. PubMed ID: 33479306
[TBL] [Abstract] [Full Text] [Related]
3. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.
Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S
Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997
[TBL] [Abstract] [Full Text] [Related]
4. clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.
Zhang MC; Fang Y; Wang L; Cheng S; Fu D; He Y; Zhao Y; Wang CF; Jiang XF; Song Q; Xu PP; Zhao WL
Clin Epigenetics; 2020 Oct; 12(1):160. PubMed ID: 33097085
[TBL] [Abstract] [Full Text] [Related]
5. Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in lymphoma.
Mondello P; Tadros S; Teater M; Fontan L; Chang AY; Jain N; Yang H; Singh S; Ying HY; Chu CS; Ma MCJ; Toska E; Alig S; Durant M; de Stanchina E; Ghosh S; Mottok A; Nastoupil L; Neelapu SS; Weigert O; Inghirami G; Baselga J; Younes A; Yee C; Dogan A; Scheinberg DA; Roeder RG; Melnick AM; Green MR
Cancer Discov; 2020 Mar; 10(3):440-459. PubMed ID: 31915197
[No Abstract] [Full Text] [Related]
6. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.
Qu X; Li H; Braziel RM; Passerini V; Rimsza LM; Hsi ED; Leonard JP; Smith SM; Kridel R; Press O; Weigert O; LeBlanc M; Friedberg JW; Fang M
Blood; 2019 Jan; 133(1):81-93. PubMed ID: 30446494
[TBL] [Abstract] [Full Text] [Related]
7. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract] [Full Text] [Related]
8. Primary Diffuse Large B-Cell lymphoma in a Patient with Rubinstein-Taybi Syndrome: Case Report and Review of the Literature.
Sy C; Henry J; Kura B; Brenner A; Grandhi R
World Neurosurg; 2018 Jan; 109():342-346. PubMed ID: 29042334
[TBL] [Abstract] [Full Text] [Related]
